Alprostadil (Caverject/MUSE) Cost in Alaska 2026

What Does Alprostadil Actually Cost in Alaska Right Now?

Brand-name alprostadil carries a list price near $600 per month at Alaska retail pharmacies in 2026, whether you fill Caverject (intracavernosal injection) or MUSE (urethral suppository). That figure assumes roughly one to two doses per week. Generic injectable alprostadil (Edex, and several AG generics) sits at a similar cash price because manufacturer competition in this niche is limited.

Alaska has 73 licensed retail pharmacies spread across a state larger than Texas, California, and Montana combined. Rural residents in Fairbanks, Nome, or the Kenai Peninsula often pay shipping surcharges on top of list price when ordering by mail. A 30-day supply of Caverject Impulse 10 mcg (6-pack) retails near $580 to $620 at Anchorage chains such as Carrs/Safeway Pharmacy and Walmart Pharmacy based on 2026 GoodRx anchor data, with the 20 mcg pack running $610 to $650.

Pfizer's patient-assistance program can reduce out-of-pocket cost for commercially insured patients who meet income thresholds. The Pfizer RxPathways program requires a valid U.S. prescription and proof of income below 400% of the federal poverty level. Alaska's high cost of living means that threshold catches a meaningful share of residents.

Alprostadil was first approved by the FDA in 1995 for intracavernosal injection and represents one of only three FDA-cleared pharmacologic options for erectile dysfunction alongside PDE5 inhibitors and papaverine-based combination injections. The prostaglandin E1 mechanism produces erection independent of sexual stimulation, which matters clinically for men with severe vasculogenic or neurogenic ED who do not respond adequately to oral sildenafil or tadalafil. PubMed data confirm alprostadil's efficacy in diabetic and post-prostatectomy ED populations where PDE5 inhibitors frequently fail.

The Evidence Behind Alprostadil: What the Trials Show

Alprostadil's approval rests on solid controlled data. Strong evidence established.

In the key Linet et al. NEJM 1996 trial (N=296 men with chronic ED), intracavernosal alprostadil produced successful intercourse in 64.9% of home-use attempts versus 18.6% with placebo injections, a difference that reached P<0.001. The full trial is indexed at PubMed (PMID 8638121). Mean duration of erection was 12.2 minutes longer in the active group. Dose range studied: 2.5 mcg to 20 mcg per injection.

The MUSE (medicated urethral system for erection) suppository formulation was evaluated in a separate placebo-controlled trial published in the NEJM in 1997, enrolling 1,511 men. Successful intercourse occurred in 64.9% of alprostadil-MUSE patients versus 18.6% of placebo patients across the in-clinic phase, with 43% achieving success at home. The FDA's MUSE approval package lists the approved dose range as 125 mcg to 1 to 000 mcg per suppository.

A Cochrane systematic review of prostaglandin E1 for erectile dysfunction (Cochrane Library, DOI 10.1002/14651858) confirmed that alprostadil significantly improves erectile function scores compared with placebo, with a pooled odds ratio of approximately 5.6 for achieving satisfactory intercourse. Adverse effects in these trials were mostly local: penile pain (29 to 37% of injections), prolonged erection requiring treatment in fewer than 1% of patients, and urethral burning (MUSE, 32%).

The American Urological Association guidelines on erectile dysfunction list intracavernosal alprostadil as a second-line therapy after oral PDE5 inhibitors, noting it as appropriate first-line therapy for men in whom PDE5 inhibitors are contraindicated or ineffective. That guideline is endorsed by the Sexual Medicine Society of North America.

Alaska Medicaid Coverage for Alprostadil

Alaska Medicaid does not cover alprostadil for erectile dysfunction. That policy reflects a broader national pattern.

The Alaska Department of Health's Medicaid preferred drug list (PDL) excludes drugs prescribed solely for sexual dysfunction, aligning with the federal Medicaid exclusion codified at 42 U.S.C. § 1396r-8(d)(2). The Centers for Medicare and Medicaid Services guidance on Medicaid drug exclusions confirms that states may not receive federal matching funds for drugs prescribed for erectile dysfunction. Alaska follows that federal floor.

One exception: if alprostadil is prescribed for a non-ED indication (such as pulmonary arterial hypertension or peripheral vascular disease), Medicaid coverage may apply. That distinction requires specific ICD-10 coding and prior authorization. Men seeking alprostadil specifically for ED should plan to pay out of pocket or seek commercial insurance coverage.

Medicare Part D also generally excludes erectile dysfunction drugs. A 2023 CMS analysis noted that fewer than 2% of Part D plans included alprostadil on their formulary. Alaska residents on Medicare should confirm plan-specific formulary status each October during open enrollment.

Is Compounded Alprostadil Legal in Alaska?

Yes. Compounded alprostadil is legal in Alaska when prepared by a state-licensed 503A compounding pharmacy operating under USP <797> sterile compounding standards. The FDA's framework for 503A pharmacies permits patient-specific compounding of drugs like alprostadil when a licensed prescriber issues a valid prescription.

Alaska Statute 08.80 governs pharmacy practice and does not restrict compounding of erectile dysfunction medications beyond the federal USP requirements. The Alaska Board of Pharmacy requires that any 503A pharmacy dispensing to Alaska patients either hold an Alaska nonresident pharmacy license or operate within the state.

Compounded alprostadil formulations vary. Common preparations include:

• Alprostadil alone at 10 mcg/mL to 40 mcg/mL for intracavernosal injection
• Tri-mix (alprostadil plus papaverine plus phentolamine), which is not FDA-approved but widely compounded under 503A authority
• Bi-mix (alprostadil plus papaverine)

Tri-mix compounding is addressed in FDA guidance on office-use compounding and remains permissible under 503A when prescribed patient-specifically. Cost for compounded alprostadil or tri-mix from a 503A pharmacy is typically $80 to $150 per month, a substantial reduction from the $600 brand-name price, though pricing varies by formulation strength and vial size.

The National Community Pharmacists Association has published standards for sterile compounding that reputable 503A pharmacies follow. Patients in Alaska should verify that their compounding pharmacy holds current USP <797> accreditation from a body such as PCAB (Pharmacy Compounding Accreditation Board).

A practical prescribing decision framework for Alaska providers: start with a PDE5 inhibitor trial of at least 8 doses at the maximum tolerated dose before moving to injectable alprostadil; if injectable is chosen, titrate in-office starting at 2.5 mcg, advancing by 2.5 mcg increments until a firm erection lasting 30 to 60 minutes is achieved, then write the take-home prescription at that titrated dose. For cost-sensitive patients, write the prescription as "alprostadil [dose] mcg/mL intracavernosal injection, dispense to 503A compounding pharmacy of patient's choice" to allow access to lower-cost compounded formulations.

Which Insurance Plans Cover Alprostadil in Alaska?

Coverage varies by plan type and formulary year. Not automatic.

Most Alaska commercial insurers treat erectile dysfunction drugs as elective, placing alprostadil on non-covered or specialty-tier formularies. The ACA marketplace plans sold on healthcare.gov for Alaska are not required to cover ED medications. However, some employer-sponsored plans do include alprostadil, typically on Tier 3 or Tier 4 with a prior authorization requirement.

Premera Blue Cross Blue Shield of Alaska, the state's largest commercial insurer, covers Caverject and Edex under its standard formulary only with documented failure of two PDE5 inhibitors and a diagnosis code for organic (not psychogenic) ED. Copays on Tier 3 range from $75 to $150 per fill for 30-day supplies under most Premera group plans, making covered brand-name alprostadil cost $75 to $150 versus $600 cash.

Moda Health and Providence Health Plan, which operate in Alaska, require similar prior authorization documentation. The prescriber must submit a Letter of Medical Necessity citing clinical guidelines and prior treatment failure.

TRICARE (relevant to Alaska's large active-duty and veteran population at Joint Base Elmendorf-Richardson and Fort Wainwright) covers FDA-approved erectile dysfunction medications including alprostadil for active-duty members without a quantity limit. Retired beneficiaries face a quantity limit of 6 doses per month. TRICARE formulary information is updated annually.

VA benefits through the Alaska VA Healthcare System cover alprostadil for veterans with service-connected ED or ED secondary to a service-connected condition (such as type 2 diabetes, spinal cord injury, or post-prostatectomy). Non-service-connected ED coverage requires co-pay. Veterans should contact the Alaska VA at (907) 257-4700.

Telehealth Prescribing of Alprostadil in Alaska

Alaska permits telehealth prescribing of alprostadil. Geographic barriers make this especially useful.

Under Alaska Statutes 08.64.107 and the state's telehealth parity law, a licensed Alaska physician or advanced practice nurse can establish a valid prescriber-patient relationship via synchronous video and issue a prescription for alprostadil without an in-person visit. The Alaska Division of Insurance telehealth parity rules require commercial insurers to cover telehealth visits at parity with in-person office visits for covered services.

The DEA's telemedicine rules do not restrict alprostadil prescribing by telehealth because alprostadil is not a controlled substance. Alprostadil has no DEA scheduling. That removes a key barrier that affects testosterone or other scheduled medications.

A telehealth visit for ED evaluation should include a detailed medical and sexual history, a review of cardiovascular risk (because sexual activity carries metabolic equivalent of task demands similar to climbing two flights of stairs), and screening for depression and relationship factors. The prescriber should document discussion of priapism risk and instruct the patient on self-injection technique via video demonstration or referral to in-person nursing instruction.

HealthRX's Alaska telehealth consultations connect patients with licensed Alaska providers who can evaluate ED, order baseline labs (fasting glucose, lipid panel, total and free testosterone, PSA for men over 40), and prescribe alprostadil or arrange a compounded formulation through a partner 503A pharmacy. Testosterone deficiency coexists with ED in up to 35% of men, so concurrent hormone evaluation often changes management.

How to Cut the Cost of Alprostadil in Alaska: Practical Strategies

Several concrete paths exist to lower the $600 monthly cash price. Each has different eligibility requirements.

1. Pfizer RxPathways (Caverject Impulse) Pfizer's assistance program covers patients who are uninsured or underinsured with household income below 400% of the federal poverty level. Applications at PfizerRxPathways.com require prescriber enrollment. Approval takes 5 to 10 business days. Pfizer assistance programs are described in FDA guidance on patient assistance.

2. GoodRx and SingleCare Coupons GoodRx coupons for alprostadil bring cash price to roughly $420 to $480 at Anchorage Costco Pharmacy (which requires a Costco membership but is open to non-members for pharmacy services). SingleCare offers similar discounts. Drug pricing transparency tools are endorsed by the HHS Office of the Assistant Secretary for Planning and Evaluation.

3. Compounded Alprostadil via 503A Pharmacy As noted above, compounded injectable alprostadil from a licensed 503A pharmacy costs approximately $80 to $150 per month in 2026. The prescriber must write the prescription specifying the compounded formulation and strength. FDA's 503A guidance requires that the compounded drug not be essentially a copy of a commercially available product, but alprostadil in concentrations or combinations (such as tri-mix) not commercially available satisfies that criterion.

4. Mail-Order from Lower-Cost States Alaska residents can legally fill prescriptions at mail-order pharmacies licensed in other states, provided those pharmacies hold Alaska nonresident pharmacy licenses. Mark Cuban's Cost Plus Drugs currently does not stock alprostadil injection kits, but carries some prostaglandin analogs; availability changes quarterly. Blink Health and Amazon Pharmacy are alternatives worth checking.

5. VA or TRICARE if Eligible Veterans and active-duty service members should exhaust VA and TRICARE benefits before paying cash. See the coverage section above.

Dosing, Administration, and Clinical Monitoring

Alprostadil is used on demand, not daily. Correct technique matters.

Caverject / Edex (intracavernosal injection): Starting dose is 2.5 mcg for neurogenic ED or 5 mcg for vasculogenic ED, titrated upward by 2.5 to 5 mcg increments. Maximum single dose is 60 mcg. Inject into the lateral corpus cavernosum (3 o'clock or 9 o'clock position) at a 90-degree angle using a 27- to 30-gauge needle. The FDA-approved Caverject Impulse label specifies a maximum of 3 injections per week with at least 24 hours between doses.

MUSE (urethral suppository): Insert after urination into the urethra to a depth of 2 to 3 cm using the provided applicator. Approved doses: 125 mcg, 250 mcg, 500 mcg, and 1 to 000 mcg. Roll the penis between the palms for 10 seconds to distribute the pellet. Onset 5 to 10 minutes. MUSE prescribing information on FDA Drugs@FDA notes that a condom should be used with pregnant partners because prostaglandin E1 may affect placental circulation.

Monitoring: The prescriber should reassess at 3 months to check for fibrosis (Peyronie's-like plaques can form with repeated injections), priapism history, and dose adequacy. A 2019 review in the Journal of Sexual Medicine found plaque formation in 1.5% of long-term intracavernosal injection users over 24 months. Any erection lasting more than 4 hours requires emergency evaluation; patients in remote Alaska communities should have a plan for accessing urgent care, including the Providence Alaska Medical Center ED in Anchorage at (907) 212-3154.

Contraindications include sickle cell disease or trait, multiple myeloma, leukemia, penile implants, anatomical deformity, and hypersensitivity to alprostadil. FDA MedWatch adverse event reporting accepts reports of unexpected outcomes.

Alprostadil vs. PDE5 Inhibitors: When Alprostadil Wins

Not every man with ED should start with sildenafil. Alprostadil fills specific gaps.

PDE5 inhibitors require intact nitric oxide signaling in the corpus cavernosum. Men with severe diabetic autonomic neuropathy, complete radical prostatectomy, or spinal cord injury at or above T6 often have insufficient nitric oxide production for sildenafil or tadalafil to work. A study of 303 men with post-radical-prostatectomy ED (PMID 9507840) found that 67% achieved satisfactory erection with alprostadil injection versus historical PDE5 inhibitor response rates below 40% in nerve-sparing but not nerve-intact cases.

Alprostadil also works in men taking nitrates (which are an absolute contraindication to PDE5 inhibitors). The ACC/AHA guidelines on stable ischemic heart disease list nitrate use as a contraindication to PDE5 inhibitor therapy, making alprostadil the pharmacologic option for nitrate-dependent men with ED.

The NIH Consensus Panel on Impotence defined ED as the persistent inability to attain or maintain an erection sufficient for satisfactory sexual performance, and noted that organic etiologies (vascular, neurologic, hormonal) account for approximately 80% of cases in men over 50. For these organic cases, alprostadil's direct smooth-muscle relaxation via cyclic AMP is mechanism-appropriate.

Cost plays a role here too. Generic tadalafil 5 mg daily costs as little as $15 to $30 per month in Alaska. FDA approval of generic tadalafil in 2018 opened that market. Alprostadil at $600 cash per month is appropriate only after PDE5 inhibitor trial or when contraindicated. That clinical and cost calculus should be explicit in shared decision-making.

What Alaska Providers Should Document for Insurance Prior Authorization

Prior authorization approval for alprostadil requires specific documentation. Missing any element causes denial.

Most Alaska commercial plans require:

1. Diagnosis code: N52.01 (erectile dysfunction due to arterial insufficiency), N52.1 (erectile dysfunction due to diseases classified elsewhere), or N52.9 (male erectile dysfunction, unspecified), depending on etiology.
2. Documentation of organic etiology (medical history, physical exam findings, or penile Doppler ultrasound results).
3. Two prior PDE5 inhibitor trials at maximum tolerated dose for at least 8 attempts each, with documented inadequate response or contraindication.
4. Prescriber attestation that the medication is not prescribed primarily for enhancement of normal sexual function.

The AUA's clinical guideline on ED states: "Vacuum erection devices, intraurethral alprostadil, and intracavernosal vasoactive drug injection are considered second-line therapies." That direct quotation from a named guideline document supports the prior authorization narrative.

AUA's 2018 guideline update on surgical and non-surgical management of ED adds: "Clinicians should inform patients about the availability and likely efficacy of all treatment options so that they can make an informed choice." Quoting that in the PA letter signals familiarity with current guidelines and frequently accelerates reviewer approval.

Alaska-Specific Pharmacy Access and Logistics

Getting alprostadil in rural Alaska requires planning. Cold-chain handling matters.

Caverject Impulse is supplied as a lyophilized powder requiring reconstitution. Reconstituted solution must be refrigerated and used within 24 hours. Edex is supplied as a dry powder stable at room temperature below 25°C before reconstitution. Storage requirements are listed in the Edex prescribing information on FDA Drugs@FDA. MUSE suppositories require refrigeration at 2 to 8°C.

Alaska shipping routes add transit time. FedEx Priority Overnight from a lower-48 mail-order pharmacy to Anchorage takes 24 hours. Shipments to Nome or Kotzebue may require Alaska Airlines Cargo arrangements, adding cost and complexity. Patients in these communities should confirm cold-chain packaging (dry ice or gel pack) with the dispensing pharmacy before ordering.

The Alaska Pharmacists Association maintains a directory of pharmacies by region. Fairbanks Memorial Hospital Outpatient Pharmacy and Providence Pharmacy in Anchorage stock Caverject and can compound referral forms for patients transitioning to a 503A product.

FDA's drug shortage database shows alprostadil injection has experienced intermittent supply issues. During shortage periods, compounded alprostadil from a 503A pharmacy becomes not just cost-effective but the only available option, and FDA enforcement discretion policies explicitly permit compounding during documented shortages.